Voyager Therapeutics, Inc. (VYGR) — Financial statements
Income statement, balance sheet, and cash flow for Voyager Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 40↓49.5% | 80↓68.0% | 250↑511.2% | 41↑9.3% | 37 | |
| Cost of Revenue | 0.00 | 0.00↓100.0% | 92↑65.3% | 56↓24.4% | 74 | |
| Gross Profit | 40↓49.5% | 80↓49.3% | 158↑1162.4% | -15↑59.2% | -36 | |
| Operating Expenses | ||||||
| R&D Expenses | 135↑5.7% | 127↑38.2% | 92↑51.7% | 61↓17.6% | 74 | |
| General & Administrative Expenses | 38↑4.5% | 36↑0.3% | 36↑15.6% | 31↓16.8% | 37 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 38↑4.5% | 36↑0.3% | 36↑15.6% | 31↓16.8% | 37 | |
| Other Expenses | 0.00 | 0.00↑100.0% | -92↓65.3% | -56↑24.4% | -74 | |
| Operating Expenses | 172↑5.5% | 163↑355.8% | 36↓0.4% | 36↓3.4% | 37 | |
| Total Costs & Expenses | 172↑5.5% | 163↑27.6% | 128↑39.5% | 92↓17.4% | 111 | |
| Operating Results | ||||||
| Operating Income | -132↓58.3% | -83↓168.3% | 122↑340.0% | -51↑30.9% | -74 | |
| Depreciation & Amortization | 4↓14.2% | 5↑6.5% | 4↓28.3% | 6↑19.9% | 5 | |
| EBITDA | -128↓62.7% | -79↓162.1% | 126↑419.0% | -40↑42.1% | -68 | |
| EBIT | -132↓58.3% | -83↓168.3% | 122↑366.2% | -46↑37.7% | -74 | |
| Interest & Other Income | ||||||
| Net Interest Income | 11↓42.1% | 18↑56.4% | 12↑554.1% | 2 | 0.00 | |
| Interest Income | 11↓42.1% | 18↑56.4% | 12↑554.1% | 2 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00↑100.0% | -5 | 0.00 | |
| Other Income / Expenses | 12↓35.3% | 19↑61.6% | 12↑163.8% | 4↑83.6% | 2 | |
| Income Before Tax | -120↓85.9% | -64↓148.1% | 134↑388.3% | -46↑34.8% | -71 | |
| Income Tax Expense | 0.14↓78.3% | 0.67↓52.8% | 1↑8700.0% | 0.02 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -120↓84.2% | -65↓149.1% | 132↑385.1% | -46↑34.8% | -71 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -120↓84.2% | -65↓149.1% | 132↑385.1% | -46↑34.8% | -71 | |
| Bottom-Line Net Income | -120↓84.2% | -65↓149.1% | 132↑385.1% | -46↑34.8% | -71 | |
| EPS (Basic) | -2.04↓80.5% | -1.13↓136.7% | 3.08↑354.5% | -1.21↑30.9% | -1.75 | |
| EPS (Diluted) | -2.04↓80.5% | -1.13↓138.0% | 2.97↑345.5% | -1.21↑30.9% | -1.75 | |
| Weighted Average Shares | 59↑1.8% | 58↑34.0% | 43↑12.2% | 38↑1.8% | 38 | |
| Weighted Average Diluted Shares | 59↑1.8% | 58↑29.4% | 45↑16.2% | 38↑1.8% | 38 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.